(Q39502253)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

4

Jun Hyuk Hong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

5

Choung-Soo Kim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

6

Hanjong Ahn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

2

Cheryn Song

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Jinsung Park

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

22 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

849-856

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Optimal management of the T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Tissue microarrays for high-throughput molecular profiling of tumor specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Prospective Evaluation of Ki–67 Labeling in Predicting the Recurrence and Progression of Superficial Bladder Transitional Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Molecular analysis of PTEN and MXI1 in primary bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Clinical value of PTEN in patients with superficial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.06.004

10.1016/J.UROLONC.2011.06.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21782482%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference